Liposomes as carriers of different new lipophilic antitumour drugs: A preliminary report

References

• Ames M. M., Kovach J. S. Parenteral formulation of hexamethylmelamine potentially suitable to use in man. Cancer Treatment Reports 1982; 66: 1579–1581
   PubMedGoogle Scholar
• Bartoli M. H., Boitard M., Fessi H., Devissagnet J. P., Picot F., Puisieux F. In vitro and in vivo antitumoral activity of free and encapsulated taxol. Journal of Microencapsulation 1990; 7(2)191–197
   PubMed Web of Science ®Google Scholar
• Denizoff F., Lang R. Rapid colorimetric assay for cellular growth and survival. Journal of Immunological Methods 1986; 89: 271
   PubMed Web of Science ®Google Scholar
• Gabizon A., Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proceedings of the National Academy of Sciences, USA 85, 6949–6953. 1988
   Google Scholar
• Gupta P. K. Drug targeting in cancer chemotherapy: a clinical perspective. Journal of Pharmaceutical Science 1980; 79(11)949–962
   Google Scholar
• Hansen M. B., Nielsen S. E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. Journal of Immunological Methods 1989; 119: 203–210
   PubMed Web of Science ®Google Scholar
• Hong C. I., Kirisitis A. J., Bucheit D. J., Nechaer A., West C. R. 1-β-D-arabinofuranosylcytosine conjugates of thioether phospholipids as a new class of potential antitumor drugs. Cancer Drug Delivery 1986; 3: 101–113
   PubMedGoogle Scholar
• Judson I. R., Calvert A. H., Rutty C. J., Abel G., Gumbell L. A., Graham M. A., Evans B. D., Wilman D. E., Ashley S. E., Carinduff F. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine). Cancer Research 1989; 49
   PubMed Web of Science ®Google Scholar
• Khokhar A. R., Al-Baker S., Brown T., Perez-Soler R. Chemical and biological studies on a series of lipid-soluble (trans-(R,R)-and-(S,S)-l,2-diaminocyclohexane) platinum(ll) complexes incorporated in liposomes. Journal of Medicinal Chemistry 1991; 34: 325–329
   PubMed Web of Science ®Google Scholar
• Kinsky S. C., Hashimoto K., Loader J. E., Knight M., Fernandes D. J. Effect of liposomes sensitized with methotrexate-dimyristoylethanolamine on cells that are resistant to methotrexate. Biochimica et Biophysica Acta 1986; 885: 129–135
   PubMed Web of Science ®Google Scholar
• Maruyama K., Kennel S. J., Huano L. Lipid composition is important for highly efficient target binding and retention of immunoliposomes. Proceedings of the National Academy of Sciences, USA 87, 5744–5748. 1990
   Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and cytotoxicity assays. Journal of Immunological Methods 1983; 65: 55
   PubMed Web of Science ®Google Scholar
• Mucci-Lo Russo P., Polin L., Bissery M., Valeriotte F., Plowman J., Luck G. D., Corbett T. H. Activity of batracylin (NSC-320846) against solid tumor of mice. Investigational New Drugs 1989; 7: 295–306
   PubMed Web of Science ®Google Scholar
• Perez-Soler R. Liposomes as carriers of antitumor agents: toward a clinical reality. Cancer Treatment Reviews 1989; 16: 67–82
   PubMed Web of Science ®Google Scholar
• Perez-Soler R., Priebe W. Anthracycline antibiotics with high liposome entrapment: structural features and biological activity. Cancer Research 1990; 50: 4260–4266
   PubMed Web of Science ®Google Scholar
• Perez-Soler R., Khokhar A. R., Lopez-Berestein G. Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R, R-l,2-diamino cyclohexane plantinum(II) encapsulated in multilamellar vesicles. Cancer Research 1987; 47: 6462–6466
   PubMed Web of Science ®Google Scholar
• Plowman J., Harrison S. D., Dykes D. J., Paull K. D., Narayanan V. L., Tobol H. K., Martin J., Grisbold D. P., JR. Preclinical antitumor activity of a picoline derivative, penclomedine (NSC-338720) on human and murine tumors. Cancer Research 1989; 49: 1909–1915
   PubMed Web of Science ®Google Scholar
• Rowinsky E. K., Cazenave L. A., Donehower R. C. Taxol: a novel investigational antimicrotubule agent. Journal of the National Cancer Institute 1990; 82: 1247–1259
   PubMed Web of Science ®Google Scholar
• Rubas W., Supersaxo A., Weder H. G., Hartmann H. R., Hengartner H., Schott H., Schwendener R. Treatment of murine LI 210 lymphoid leukaemia and B16 melanoma with lipophyllic cytosine arabinoside prodrugs incorporated into unilaminar liposomes. International Journal of cancer 1986; 37: 149–154
   PubMed Web of Science ®Google Scholar
• Visnuvajjala K., Cradock J. C. Tricyclo [4.2.2.0]-dec-9-ene-3,4,7,8-tetracarboxylic acid diimide: formulation and stability studies. Science 1986; 75: 301–303
   Google Scholar
• Yatvin M. B., Lelkes P. I. Clinical prospects for liposomes. Medical Physics 1982; 9(2)149–174
   PubMed Web of Science ®Google Scholar